Verona Pharma’s investor and R&D webinar yesterday was an excellent example of the unmet need for a novel therapy in the 1.2m COPD patients that remain symptomatic despite maximum therapy. The event focused on the problems and opportunities arising from COPD, and brought together a group of leading pulmonologists representing the clinical community for a panel discussion (see below for key KOL takeaways). The event reinforced our confidence that ensifentrine has an important role as
02 Jun 2020
Investor/R&D day highlights unmet need in symptomatic COPD patients
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Investor/R&D day highlights unmet need in symptomatic COPD patients
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
02 Jun 2020 -
Author:
Edward Thomason -
Pages:
3
Verona Pharma’s investor and R&D webinar yesterday was an excellent example of the unmet need for a novel therapy in the 1.2m COPD patients that remain symptomatic despite maximum therapy. The event focused on the problems and opportunities arising from COPD, and brought together a group of leading pulmonologists representing the clinical community for a panel discussion (see below for key KOL takeaways). The event reinforced our confidence that ensifentrine has an important role as